Press releases

Investment continues alliance for percutaneous mitral valve replacement established in 2012

Up to $25,000 in prizes to be awarded to winners

Clinical and economic data to be presented at world's leading interventional cardiology meeting

New category of drug-eluting stent approved for U.S. patients

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended Oct. 28, 2015. Learn how to tune in.

Provides minimally invasive alternative to an esophagectomy

MAJESTIC trial data support strong safety profile with low target lesion revascularization rate

System includes first directional lead with current steering and expanded programming flexibility

Boston Scientific will participate in the Morgan Stanley healthcare conference on Sept. 17, 2015. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on Sept. 9, 2015. Learn how to watch the webcast or replay.

Updated labeling allows backwards-compatibility for MRI scans for the industry's longest-lasting ICD and CRT-D systems

U.S. launch underway for therapy designed to treat Peripheral Artery Disease

Men’s health and prostate health acquisition positions Boston Scientific as a urology leader

Strategic alliance to expand Boston Scientific portfolio of remote monitoring solutions

"Our strong performance in the second quarter reflects the consistent execution of our global teams," said Mike Mahoney, CEO of Boston Scientific.

First guidewire designed specifically for TAVI/R now sized for smaller ventricles

First Patients Enrolled in the FAST Feasibility Study

Chairman Pete Nicholas welcomes James as a business leader with “significant financial knowledge, HR management and organizational planning skills.”

Demonstrates growing clinical acceptance for novel, procedure-based treatment option for severe asthma

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ending June 15, 2015. Learn how to tune in.

Study to evaluate patients implanted with S-ICD for primary prevention of sudden cardiac death in the setting of severely reduced cardiac function

Spinal cord stimulator (SCS) system provided 1.5x better overall pain relief and 2x better low back pain relief than previous generation system

World's smallest 16-contact high-capacity primary cell device expands spinal cord stimulator system (SCS) offering

Boston Scientific will participate in the healthcare conference on June 9, 2015. Learn how to watch the webcast or replay.

Compelling results presented at EuroPCR 2015 add to growing body of evidence supporting performance and safety

Additional data from EVOLVE II pivotal trial demonstrate safety and performance in patients with diabetes at one year

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes

Key data from 42 abstracts to include presentations on the WATCHMAN device and the EMBLEM S-ICD system.

Boston Scientific Corporation (NYSE: BSX) announced its pricing of a public offering of senior notes

Recognition from Shingo Institute is the second in two years for a company facility

CEO Mike Mahoney will outline company's unique opportunities to bring forward meaningful innovation

Customized programs to drive operational and care pathway improvements

"We achieved strong results in the first quarter and continue to build global momentum," said CEO Mike Mahoney

MAJESTIC trial meets performance endpoint with compelling results

Boston Scientific will participate in an upcoming healthcare conference on May 12, 2015. A live webcast and replay will be available.

Collaboration provides patients and physicians a comprehensive portfolio for Deep Brain Stimulation (DBS) therapy

Boston Scientific will participate in an upcoming healthcare conference on May 6, 2015. A live webcast and replay will be available.

Results published in the Journal of American College of Cardiology

Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the...

Companies plan to accelerate physician training and expand utilization of less-invasive endoscopy technologies in China

Acquisition will bring minimally invasive devices for Endoscopic Ultrasound (EUS) into company portfolio

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 on April 28, 2015. Learn how to tune in.

Novel stroke risk reduction option for indicated patients with atrial fibrillation

Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest

First-of-its-kind alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation

Chairman Pete Nicholas welcomed the two new board members: "Their extensive experience and management insights will be valuable additions."

Combined business to advance patient care with leading solutions across major urology categories

Boston Scientific will participate in an upcoming healthcare conference on March 10, 2015. A live webcast and replay will be available.

New-generation system is designed to optimize procedural efficiency and productivity

Boston Scientific will participate in an upcoming healthcare conference on March 4, 2015. A live webcast and replay will be available.

Action against Guidant stemmed from Boston Scientific's acquisition

Boston Scientific will participate in the upcoming healthcare conference on Feb. 25, 2015. A live webcast and replay will be available. Read more.

Boston Scientific will participate in the upcoming healthcare conference on Feb. 11, 2015. A live webcast and replay will be available. Read more.

Agreement provides physicians with a comprehensive solution to prepare and treat diseased femoropopliteal vessels

"2014 was another year of significant achievement for Boston Scientific," said Mike Mahoney, chairman and CEO

IndustryWeek recognition highlights manufacturing excellence

Implantable cardioverter defibrillators projected to last nearly 12 years, double the battery capacity of other ICDs

Competition to showcase innovative ideas and encourage entrepreneurialism among early-stage medical device companies

Boston Scientific will host and webcast an Investor Day business review meeting on May 1, 2015. Learn how to tune in or watch the replay.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and FY ended Dec. 31, 2014. Learn how to tune in.

Boston Scientific will participate in the upcoming healthcare conference on Jan. 13, 2015. A live webcast and replay will be available. Read more.

Boston Scientific will participate in the upcoming healthcare conference on Jan. 6, 2015. A live webcast and replay will be available. Read more.

Significant relief achieved using Advanced Illumina™ 3D programming software

Highest rating of 100 percent distinguishes company as one of the "Best Places to Work for LGBT Equality"

EVOLVE II trial represents the first successful U.S. pivotal trial of a bioabsorbable polymer stent

System designed for the hysteroscopic removal of interuterine fibroids and polyps

New CPT Category I code facilitates processing for U.S. hospitals and physicians

Boston Scientific will participate in the upcoming healthcare conference on November 18, 2014. A live webcast and replay will be available.

Event will be held in Chicago, site of the 2014 American Heart Association Scientific sessions

Data will focus on long-term back pain relief using the Precision Spectra™ Spinal Cord Stimulator (SCS) System and highlight research on stimulation waveforms

Boston Scientific will participate in the upcoming healthcare conference on November 11, 2014. A live webcast and replay will be available.

"We achieved excellent third quarter results,” said Mike Mahoney, Boston Scientific chairman and CEO

World's first 32-contact SCS surgical leads designed to provide more focused pain relief for patients with chronic pain

PLATINUM diversity trial evaluating performance in women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease

Innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems

Comprehensive clinical data from randomized trials reviewed

Boston Scientific will webcast its conference call discussing financial results and business highlights for Q3 ended September 30, 2014. Learn how to tune in.

Data from REPRISE III clinical trial designed to support U.S. regulatory approval

First DBS system to offer precise neural targeting and a 25-year battery life

No cases of moderate or severe paravalvular aortic regurgitation at one year

Data will focus on areas of significant unmet patient need, including Coronary Artery Disease and Aortic Valve Disease

Boston Scientific will participate in the upcoming healthcare conference on September 17, 2014 in London

Acquisition allows Boston Scientific to offer a more complete portfolio of solutions to treat challenging vascular conditions

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure

Boston Scientific will participate in the healthcare conference on September 8 in New York

Companies reach agreement to develop a new and differentiated FFR guidewire and next generation Boston Scientific Rotablator™ RotaWire™

"We had a strong second quarter, delivering balanced growth across our divisions," said CEO Mike Mahoney

Innovative technology adds to company's leading portfolio of treatment options for Coronary Artery Disease

Easy to use imaging system to support planned intravascular ultrasound and fractional flow reserve products

Advanced bare-metal stent provides additional treatment option for interventional cardiologists and patients

European launch means physicians can now choose from three available valve sizes to match patient anatomy more precisely

Innovative technology strengthens company's leading portfolio of solutions for peripheral vascular disease

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2014. Learn how to tune in.

Data presented at the 18th International Congress of Parkinson's Disease and Movement Disorders demonstrate highly significant improvement in motor function for patients with Parkinson's Disease

Data presented at the International Congress of Parkinson's Disease and Movement Disorders demonstrate superior therapeutic window for the treatment of Parkinson's Disease

Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world

Boston Scientific will participate in the healthcare conference on June 17 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on June 10. Learn how to watch the webcast or replay.

Study evaluated Lotus Valve System in symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement

EVOLVE study data presented today at EuroPCR 2014 also demonstrate excellent safety profile